ES2075169T3 - Agentes de union especifica. - Google Patents

Agentes de union especifica.

Info

Publication number
ES2075169T3
ES2075169T3 ES90312407T ES90312407T ES2075169T3 ES 2075169 T3 ES2075169 T3 ES 2075169T3 ES 90312407 T ES90312407 T ES 90312407T ES 90312407 T ES90312407 T ES 90312407T ES 2075169 T3 ES2075169 T3 ES 2075169T3
Authority
ES
Spain
Prior art keywords
human
reformed
specific union
agents
union agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90312407T
Other languages
English (en)
Inventor
Martine Elisa Verhoeyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever NV
Original Assignee
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898926045A external-priority patent/GB8926045D0/en
Priority claimed from GB909019552A external-priority patent/GB9019552D0/en
Application filed by Unilever NV filed Critical Unilever NV
Application granted granted Critical
Publication of ES2075169T3 publication Critical patent/ES2075169T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Fireproofing Substances (AREA)
  • Paper (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Dental Preparations (AREA)

Abstract

ANTICUERPO HUMANO REFORMADO O FRAGMENTO DE ANTICUERPO REFORMADO HUMANO CON UNA ESPECIFIDAD PARA EL FOSFATASO ALCALINO DE PLACENTA HUMANA (PLAP) QUE SE PRODUCE MEDIANTE LA TRANSFERENCIA DE LAS REGIONES QUE DETERMINAN COMPLEMENTARIAMENTE (CDRS) DE UNA CADENA CELULAR DE HIBRIDOMA ANTI-PLAP DE MURINA H17E2 EN UN MARCO DE UNA REGION VARIABLE DE ANTICUERPOS HUMANOS. LA MOLECULA REFORMADA SE PUEDE UTILIZAR EN EL TRATAMIENTO O EL DIAGNOSTICO DEL CANCER.
ES90312407T 1989-11-17 1990-11-14 Agentes de union especifica. Expired - Lifetime ES2075169T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898926045A GB8926045D0 (en) 1989-11-17 1989-11-17 Specific binding agents
GB909019552A GB9019552D0 (en) 1990-09-07 1990-09-07 Specific binding agents

Publications (1)

Publication Number Publication Date
ES2075169T3 true ES2075169T3 (es) 1995-10-01

Family

ID=26296218

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90312407T Expired - Lifetime ES2075169T3 (es) 1989-11-17 1990-11-14 Agentes de union especifica.

Country Status (16)

Country Link
EP (1) EP0429242B1 (es)
JP (1) JPH05501357A (es)
KR (2) KR970007783B1 (es)
AT (1) ATE123815T1 (es)
AU (1) AU652923B2 (es)
BG (1) BG60687B1 (es)
CA (1) CA2066670A1 (es)
DE (1) DE69020112T2 (es)
DK (1) DK0429242T3 (es)
ES (1) ES2075169T3 (es)
FI (1) FI922220L (es)
GR (1) GR3017407T3 (es)
HU (1) HUT64600A (es)
NO (2) NO303066B1 (es)
RO (1) RO110262B1 (es)
WO (1) WO1991007500A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
JP5297742B2 (ja) * 2008-09-26 2013-09-25 株式会社青木科学研究所 金型用粉体含有油性潤滑剤、これを用いた静電塗布方法、及び静電塗布装置
ES2975747T3 (es) * 2015-11-30 2024-07-12 Univ California Administración de carga útil específica de tumor y activación inmunitaria utilizando un anticuerpo humano que se dirige a un antígeno de superficie celular de tumor altamente específico
EP3806894A4 (en) 2018-06-12 2022-06-08 Promab Biotechnologies, Inc. PLAP-CAR EFFECTOR CELLS
CA3209579A1 (en) 2021-01-27 2022-08-04 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof
IL311570A (en) * 2021-10-14 2024-05-01 Arsenal Biosciences Inc Immune cells with common expression chain and logic gate systems
CN114014933B (zh) * 2021-11-17 2023-05-02 福州迈新生物技术开发有限公司 抗plap蛋白单克隆抗体、细胞系及其制备方法和应用
WO2025048716A1 (en) * 2023-08-25 2025-03-06 Axcynsis Therapeutics Pte. Ltd. Anti-alpp/alppl2 antibodies, antibody-drug conjugates, and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product

Also Published As

Publication number Publication date
EP0429242A2 (en) 1991-05-29
DE69020112T2 (de) 1995-11-02
EP0429242A3 (en) 1991-06-05
NO921941L (no) 1992-05-15
HUT64600A (en) 1994-01-28
EP0429242B1 (en) 1995-06-14
JPH05501357A (ja) 1993-03-18
FI922220A7 (fi) 1992-05-15
BG96346A (bg) 1993-12-24
RO110262B1 (ro) 1995-11-30
DE69020112D1 (de) 1995-07-20
NO980656L (no) 1992-05-15
FI922220A0 (fi) 1992-05-15
CA2066670A1 (en) 1991-05-18
FI922220L (fi) 1992-05-15
ATE123815T1 (de) 1995-06-15
KR920703837A (ko) 1992-12-18
WO1991007500A1 (en) 1991-05-30
KR970007783B1 (ko) 1997-05-16
BG60687B1 (bg) 1995-12-29
NO303066B1 (no) 1998-05-25
DK0429242T3 (da) 1995-10-16
NO980656D0 (no) 1998-02-16
HU9201619D0 (en) 1992-08-28
AU6736990A (en) 1991-06-13
KR970007782B1 (ko) 1997-05-16
NO921941D0 (no) 1992-05-15
AU652923B2 (en) 1994-09-15
GR3017407T3 (en) 1995-12-31

Similar Documents

Publication Publication Date Title
ES2193129T3 (es) Ligantes especificos.
ES2128362T3 (es) Fragmentos de proteinas de prion.
ES2124250T3 (es) Anticuerpo especifico para un antigeno tumoral.
BG101024A (bg) Моноклонално антитяло срещу сd44v6
ES2173910T3 (es) Anticuerpos humanizados dirigidos contra el antigeno a33.
ES2196073T3 (es) Prueba inmunologica de agentes farmacologicos facilitada con detergente.
ES2050114T3 (es) Anticuerpos monoclonales humanos para el virus asociado a la linfoadenopatia.
IT7829543A0 (it) Metodo e composizioni per la determinazione diretta del ferro nel siero ematico.
DK199779A (da) Renset antigen til undersoegelse for neisseria gonorrhoeae antistoffer
ES2091292T3 (es) Metodo para la determinacion inmunologica del polipeptido carboxiterminal de procolageno de tipo i.
SE8403630D0 (sv) Humana proteiner
ES520012A0 (es) Procedimiento de aglutinacion con latex para la deteccion o la determinacion de un participante en una reaccion inmunologica.
ES2042461T3 (es) Producto y procedimiento para el teñido oxidativo del cabello.
SE8007074L (sv) Glukagonfragment jemte dess anvendning
ATE123815T1 (de) Spezifische bindende wirkstoffe.
ES2101695T3 (es) Haptoglobina relacionada con el cancer (hpr).
ATE2049T1 (de) Mittel zur therapie von immunkomplexerkrankungen.
ES2044893T3 (es) Un anticuerpo monoclonal especifico para un inhibidor de la coagulacion.
ATE4282T1 (de) Verfahren zur herstellung von toxoplasmenbereitungen fuer die toxoplasmosediagnose und die so hergestellten bereitungen.
ES8707555A1 (es) Procedimiento para la determinacion inmunologica del proteoglicano sulfato de heparano
Ige Grillo et al. A fluorescent histochemical method for the detection of tissue disulphide groups
EP0622082A4 (en) IMMUNE COMPLEX.
AR211696A1 (es) Un procedimiento para la preparacion de un suero para la determinacion de la presencia de antigenos que son especificos del embarazo,en la sangre de un mamifero
SU33445A1 (ru) Способ приготовлени гипсового в жущего вещества
IT7830061A0 (it) Metodo radioimmunologico per la determinazione della funzione tiroidea mediante un saggio in vitro su siero del sangue.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 429242

Country of ref document: ES